A2A Agonists Market Size, Share, and Industry Analysis, By Application (Myocardial Perfusion Imaging, and Others), By End User (Hospitals, Diagnostic Imaging Centers, Specialty Clinics, Research Institutes, and Others), and Regional Forecast till 2034

The global A2A agonists market was valued at USD 0.35 billion in 2025. The market is projected to grow from USD 0.41 billion in 2026 to USD 1.40 billion by 2034, exhibiting a CAGR of 14.6% during the forecast period.

The market is a niche but clinically important segment within cardiovascular diagnostics and drug development. The market is currently led by regadenoson-based injectable products, which are used as pharmacologic stress agents during radionuclide myocardial perfusion imaging in patients who are unable to undergo adequate exercise stress. The product demand is supported by the growing use of non-invasive cardiac imaging, rising diagnosis of coronary artery disease, and the need for safer and more convenient pharmacologic stress testing options. Although the commercial market is presently concentrated around IV regadenoson products, continued research into A2A receptor biology may create future opportunities in inflammation, tissue protection, wound healing, and pain-related indications if pipeline candidates demonstrate strong clinical and safety outcomes.

• For instance, in August 2024, Indies Pharma received a New Drug Application from the U.S. FDA for Regadenoson injection, 0.4MG/5ML (0.08MG/ML) Single Dose PFS (Pre-Filled Syringe). Regadenoson is indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.

Furthermore, the increasing prevalence of cardiovascular diseases, regulatory approval and new product launches, and partnerships by key operating companies strengthen their market position and support overall market growth.

A2A Agonists Market Driver

Rising Burden of Cardiovascular Diseases to Increase Demand for Pharmacologic Stress Testing

The soaring burden of cardiovascular diseases is increasing the need for accurate and non-invasive cardiac evaluation, which directly supports demand for A2A agonists used in pharmacologic stress testing. Many patients with suspected coronary artery disease are elderly, physically limited, or unable to perform adequate exercise stress, creating a stronger need for drug-based stress agents that can simulate exercise-like coronary blood flow changes during imaging. As a result, regadenoson-based A2A agonists are gaining commercial importance in hospitals, diagnostic imaging centers, and nuclear cardiology labs as they help clinicians assess myocardial perfusion in patients who cannot complete treadmill-based testing.

• For instance, in February 2022, GE Healthcare received approval from the European Commission for its stress agent Rapiscan (regadenoson) for use in additional imaging modalities, including stress cardiac magnetic resonance imaging. The Rapiscan was already used in SPECT myocardial perfusion imaging and serves as an alternative for adult patients who cannot exercise adequately, supporting its role in coronary artery disease diagnosis.

Download Free sample to learn more about this report.

A report published by the Centers for Disease Control and Prevention (CDC) in October 2024 states that, in 2021, heart disease was the leading cause of death for people of most racial and ethnic groups in the U.S. These include African American, American Indian, Alaska Native, Hispanic, and White men.  

A2A Agonists Market Restraint

Safety Concerns and Use Restrictions May Restrain the Wider Product Adoption

Safety concerns associated with pharmacologic cardiac stress agents may restrain the wider adoption of A2A agonists in some patient groups. Regadenoson-based products are used to increase coronary blood flow during myocardial perfusion imaging, but this same pharmacologic effect can create risk in patients with unstable cardiac conditions. As a result, clinicians need to screen patients carefully, avoid use in patients with signs of acute myocardial ischemia or cardiovascular instability, and ensure that trained staff and resuscitation equipment are available before administration. This increases procedural caution and limits use in higher-risk patients, which can restrain market growth despite the product’s established role in cardiac imaging.

• For instance, in 2025, a JACC Case Reports publication highlighted an instance where four patients developed ST-segment elevation myocardial infarction or STEMI-equivalent events after intravenous regadenoson administration during pharmacologic radionuclide myocardial perfusion imaging. The report noted that although regadenoson is generally considered safe and widely used, serious cardiovascular complications can occur, which supports the restraint that safety concerns and careful patient screening may limit the wider product use in high-risk cardiac patients.

A2A Agonists Market Opportunity

Expansion of Regadenoson Use beyond SPECT Imaging to Create New Diagnostic Opportunities

The expansion of regadenoson use beyond traditional SPECT myocardial perfusion imaging creates a strong growth opportunity for market players. Regadenoson is already established as a pharmacologic stress agent for patients who cannot perform adequate exercise stress. Still, its use across additional cardiac imaging modalities can increase the number of eligible procedures. As cardiac MRI, PET, and CT-based cardiac imaging gain more clinical attention, regadenoson can support broader diagnostic workflows by helping clinicians assess coronary blood flow in a wider range of imaging settings. This creates an opportunity for manufacturers to expand product utilization beyond the conventional nuclear cardiology base and capture demand from advanced cardiac imaging centers.

• For instance, in March 2025, GE HealthCare launched new cardiology innovations in the U.S., including Flyrcado, a first-of-its-kind unit-dose PET myocardial perfusion imaging agent for the detection of coronary artery disease. The Flyrcado was available in select U.S. markets and had received traditional pass-through payment status from CMS.

Segmentation

Key Insights

The report covers the following key insights:

• Pipeline Analysis, By Key Players
• Regulatory Scenario, By Key Countries/Regions
• New Product Launches and Indication Expansions, By Key Players
• Key Industry Developments (Mergers, Collaborations, and Acquisitions)

Analysis by Application

Based on application, the global A2A agonists market is segmented into myocardial perfusion imaging and others.

The myocardial perfusion imaging segment is expected to dominate the global market. The dominance of the segment is due to the commercial availability of A2A agonist products used as pharmacologic stress agents during radionuclide myocardial perfusion imaging. The segment dominates as regadenoson-based products are specifically indicated for patients who are unable to undergo adequate exercise stress, making them highly relevant in hospitals and cardiac imaging centers that handle elderly, high-risk, or exercise-limited patients.

• For instance, in March 2023, Meitheal Pharmaceuticals launched Regadenoson Injection 0.4 mg/5 mL pre-filled syringe. The product is used as a pharmacologic stress agent for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.

Analysis by End User

Based on end user, the market is segmented into hospitals, diagnostic imaging centers, specialty clinics, research institutes, and others.

The hospitals segment is anticipated to dominate the global A2A agonists market. Regadenoson-based products are injectable pharmacologic stress agents used in controlled diagnostic settings where cardiac monitoring, trained staff, radiopharmaceutical handling, and emergency support are available. Hospitals have a larger patient inflow for suspected coronary artery disease, broader access to nuclear cardiology departments, and stronger institutional procurement systems than standalone clinics. As a result, hospitals account for the largest use of A2A agonists, while diagnostic imaging centers and specialty clinics contribute reasonable but comparatively smaller demand.

• For instance, in November 2024, Baxter International Inc launched five new injectable pharmaceutical products in the U.S.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, on the basis of geography, has been analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 45.0% of the global A2A agonists market in 2025. The regional market is growing owing to the presence of  a well-established base of hospitals, nuclear cardiology labs, and diagnostic imaging centers that routinely use pharmacologic stress testing for patients who cannot perform adequate exercise stress. Since regadenoson is used as a pharmacologic stress agent for myocardial perfusion imaging, demand remains closely linked to the high volume of cardiac diagnostic procedures in the U.S. At the same time, increasing availability of generic regadenoson injections is improving price access and strengthening institutional procurement, which supports wider use across hospital and outpatient imaging settings.

• For instance, in May 2022, Amphastar Pharmaceuticals announced that the U.S. FDA approved its ANDA for Regadenoson Injection, 0.08 mg/mL, 5 mL single-dose pre-filled syringe. The regadenoson is indicated for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress and the FDA determined its product to be bioequivalent and therapeutically equivalent to Lexiscan.

The Europe A2A agonists market is expected to grow at a significant CAGR during the forecast period. The market is expanding as regadenoson-based products are already established in myocardial perfusion imaging, and European healthcare systems continue to invest in advanced cardiac diagnostic pathways. The market benefits from the need to diagnose coronary artery disease in older and exercise-limited patients, where pharmacologic stress agents provide an important alternative to treadmill-based testing.

• For instance, in February 2022, GE HealthCare received approval from the European Commission for Rapiscan / regadenoson for use in additional imaging modalities. This would expand the solution’s role from SPECT myocardial perfusion imaging to stress cardiac MRI and other cardiac imaging applications.

Asia Pacific is expected to grow at a stable CAGR during the forecast period. The region is growing as it is witnessing the rising demand for cardiovascular diagnostics, expanding hospital infrastructure, and increasing use of advanced imaging services in major countries. This supports long-term market growth as local and regional manufacturers can improve supply availability, lower product costs, and participate in global institutional demand for injectable pharmacologic stress agents.

• For instance, in January 2022, Glenmark Pharmaceuticals received tentative approval from the U.S. FDA for Regadenoson Injection, 0.4 mg/5 mL single-dose pre-filled syringe. The product is a generic version of Lexiscan and is used for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.

Key Players Covered

The global A2A agonists market is highly consolidated.

The report includes the profiles of the following key players:

• Astellas Pharma Inc. (Japan)
• GE HealthCare Technologies Inc. (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Reddy’s Laboratories Ltd. (India)
• Meitheal Pharmaceuticals, Inc. (U.S.)
• Baxter Healthcare Corporation (U.S.)
• Pfizer Inc. (U.S.)
• Aurobindo Pharma Ltd. (India)
• Gland Pharma Limited (India)
• Mylan Institutional LLC (Viatris) (U.S.)

Key Industry Developments

• April 2024: Baxter International Inc., a global leader in injectables, anesthesia, and drug compounding, announced the continued expansion of its Pharmaceuticals portfolio with five injectable product launches in the U.S.
• May 2023: Reddy's Laboratories Ltd., along with its subsidiaries, launched Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of Lexiscan (Regadenoson) injection, approved by the U.S. FDA.